These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24026661)

  • 1. High level of p37δ-mRNA relative to p110δ-mRNA in neuroblastoma tumors correlates with poor patient survival.
    Fransson S; Ejeskär K
    Med Oncol; 2013 Dec; 30(4):724. PubMed ID: 24026661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p37δ is a new isoform of PI3K p110δ that increases cell proliferation and is overexpressed in tumors.
    Fransson S; Uv A; Eriksson H; Andersson MK; Wettergren Y; Bergo M; Ejeskär K
    Oncogene; 2012 Jul; 31(27):3277-86. PubMed ID: 22020336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Unique Non-Catalytic C-Terminus of P37delta-PI3K Adds Proliferative Properties In Vitro and In Vivo.
    Ejeskär K; Vickes O; Kuchipudi A; Wettergren Y; Uv A; Rotter Sopasakis V
    PLoS One; 2015; 10(5):e0127497. PubMed ID: 26024481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stage-dependent expression of PI3K/Akt‑pathway genes in neuroblastoma.
    Fransson S; Abel F; Kogner P; Martinsson T; Ejeskär K
    Int J Oncol; 2013 Feb; 42(2):609-16. PubMed ID: 23232578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aggressive neuroblastomas have high p110alpha but low p110delta and p55alpha/p50alpha protein levels compared to low stage neuroblastomas.
    Fransson S; Kogner P; Martinsson T; Ejeskär K
    J Mol Signal; 2013 Apr; 8(1):4. PubMed ID: 23597230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells.
    Boller D; Schramm A; Doepfner KT; Shalaby T; von Bueren AO; Eggert A; Grotzer MA; Arcaro A
    Clin Cancer Res; 2008 Feb; 14(4):1172-81. PubMed ID: 18281552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
    Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
    Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma.
    Santo EE; Stroeken P; Sluis PV; Koster J; Versteeg R; Westerhout EM
    Cancer Res; 2013 Apr; 73(7):2189-98. PubMed ID: 23378341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma.
    Mohlin S; Hamidian A; von Stedingk K; Bridges E; Wigerup C; Bexell D; Påhlman S
    Cancer Res; 2015 Nov; 75(21):4617-28. PubMed ID: 26432405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
    Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
    J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.
    Iyengar S; Clear A; Bödör C; Maharaj L; Lee A; Calaminici M; Matthews J; Iqbal S; Auer R; Gribben J; Joel S
    Blood; 2013 Mar; 121(12):2274-84. PubMed ID: 23341541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in PIK3CA are infrequent in neuroblastoma.
    Dam V; Morgan BT; Mazanek P; Hogarty MD
    BMC Cancer; 2006 Jul; 6():177. PubMed ID: 16822308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K/Akt signaling pathway triggers P2X7 receptor expression as a pro-survival factor of neuroblastoma cells under limiting growth conditions.
    Gómez-Villafuertes R; García-Huerta P; Díaz-Hernández JI; Miras-Portugal MT
    Sci Rep; 2015 Dec; 5():18417. PubMed ID: 26687764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CD induces cell growth and invasion by activating AKT/GSK-3β/β-catenin signaling in colorectal cancer.
    Chen JS; Huang JQ; Luo B; Dong SH; Wang RC; Jiang ZK; Xie YK; Yi W; Wen GM; Zhong JF
    Cancer Sci; 2019 Mar; 110(3):997-1011. PubMed ID: 30618098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The catalytic PI3K isoforms p110gamma and p110delta contribute to B cell development and maintenance, transformation, and proliferation.
    Beer-Hammer S; Zebedin E; von Holleben M; Alferink J; Reis B; Dresing P; Degrandi D; Scheu S; Hirsch E; Sexl V; Pfeffer K; Nürnberg B; Piekorz RP
    J Leukoc Biol; 2010 Jun; 87(6):1083-95. PubMed ID: 20200404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PI3K/AKT signaling pathway: Associations of miRNAs with dysregulated gene expression in colorectal cancer.
    Slattery ML; Mullany LE; Sakoda LC; Wolff RK; Stevens JR; Samowitz WS; Herrick JS
    Mol Carcinog; 2018 Feb; 57(2):243-261. PubMed ID: 29068474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic signaling of class I PI3K isoforms.
    Denley A; Kang S; Karst U; Vogt PK
    Oncogene; 2008 Apr; 27(18):2561-74. PubMed ID: 17998941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas.
    Knobbe CB; Reifenberger G
    Brain Pathol; 2003 Oct; 13(4):507-18. PubMed ID: 14655756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
    Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
    Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.